JP2017511386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017511386A5 JP2017511386A5 JP2017506256A JP2017506256A JP2017511386A5 JP 2017511386 A5 JP2017511386 A5 JP 2017511386A5 JP 2017506256 A JP2017506256 A JP 2017506256A JP 2017506256 A JP2017506256 A JP 2017506256A JP 2017511386 A5 JP2017511386 A5 JP 2017511386A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ptz
- hypersomnia
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 40
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 claims 27
- 229960005152 pentetrazol Drugs 0.000 claims 27
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 15
- 206010020765 hypersomnia Diseases 0.000 claims 15
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000007958 sleep Effects 0.000 claims 6
- 208000032140 Sleepiness Diseases 0.000 claims 4
- 206010041349 Somnolence Diseases 0.000 claims 4
- 230000037321 sleepiness Effects 0.000 claims 4
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 3
- 230000003111 delayed effect Effects 0.000 claims 3
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 230000000422 nocturnal effect Effects 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- 102100035785 Acyl-CoA-binding protein Human genes 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 108010039287 Diazepam Binding Inhibitor Proteins 0.000 claims 1
- 208000033409 Narcolepsy type 2 Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000025535 REM sleep behavior disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000010513 Stupor Diseases 0.000 claims 1
- 230000003281 allosteric effect Effects 0.000 claims 1
- 229940125516 allosteric modulator Drugs 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 208000009808 cranioectodermal dysplasia Diseases 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000028511 narcolepsy without cataplexy Diseases 0.000 claims 1
- 208000023046 narcolepsy-cataplexy syndrome Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000005439 recurrent hypersomnia Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 230000004620 sleep latency Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461979918P | 2014-04-15 | 2014-04-15 | |
| US61/979,918 | 2014-04-15 | ||
| PCT/US2015/025696 WO2015160766A1 (en) | 2014-04-15 | 2015-04-14 | Methods for treating hypersomnia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036646A Division JP2020105200A (ja) | 2014-04-15 | 2020-03-04 | 過眠症を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017511386A JP2017511386A (ja) | 2017-04-20 |
| JP2017511386A5 true JP2017511386A5 (enExample) | 2018-06-07 |
| JP6672264B2 JP6672264B2 (ja) | 2020-03-25 |
Family
ID=54324484
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506256A Expired - Fee Related JP6672264B2 (ja) | 2014-04-15 | 2015-04-14 | 過眠症を治療するための方法 |
| JP2020036646A Pending JP2020105200A (ja) | 2014-04-15 | 2020-03-04 | 過眠症を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020036646A Pending JP2020105200A (ja) | 2014-04-15 | 2020-03-04 | 過眠症を治療するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10688103B2 (enExample) |
| EP (1) | EP3131904A4 (enExample) |
| JP (2) | JP6672264B2 (enExample) |
| KR (1) | KR20170005415A (enExample) |
| CN (1) | CN106459066B (enExample) |
| AU (2) | AU2015247829B2 (enExample) |
| CA (1) | CA2945705A1 (enExample) |
| EA (1) | EA201692061A1 (enExample) |
| IL (1) | IL248255A0 (enExample) |
| MX (1) | MX2016013340A (enExample) |
| WO (1) | WO2015160766A1 (enExample) |
| ZA (1) | ZA201607068B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| US11529358B2 (en) | 2017-05-10 | 2022-12-20 | Emory University | Treatment of conditions associated with myotonic dystrophy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006137746A (ja) | 2004-10-13 | 2006-06-01 | Otsuka Pharmaceut Factory Inc | オレキシン誘導組成物 |
| CA2686155C (en) | 2006-05-22 | 2016-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| JP2010515882A (ja) * | 2007-01-05 | 2010-05-13 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 睡眠関連障害を含むｇａｂａ関連神経学的障害を処置するためのｇタンパク質共役受容体およびその調節因子 |
| US9616070B2 (en) * | 2008-03-12 | 2017-04-11 | Emory University | Use of GABAA receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness |
| US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
| US8946206B2 (en) * | 2010-12-17 | 2015-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for improving cognitive function |
| JP2014511382A (ja) | 2011-02-23 | 2014-05-15 | コエルルウス リミテッド | フルマゼニル錯体、それを含む組成物、およびその使用 |
| ES2579319T3 (es) | 2011-05-04 | 2016-08-09 | Balance Therapeutics, Inc. | Derivados de pentilenotetrazol |
-
2015
- 2015-04-14 AU AU2015247829A patent/AU2015247829B2/en not_active Ceased
- 2015-04-14 JP JP2017506256A patent/JP6672264B2/ja not_active Expired - Fee Related
- 2015-04-14 US US15/303,725 patent/US10688103B2/en active Active
- 2015-04-14 CN CN201580031853.4A patent/CN106459066B/zh not_active Expired - Fee Related
- 2015-04-14 EP EP15780466.7A patent/EP3131904A4/en not_active Withdrawn
- 2015-04-14 WO PCT/US2015/025696 patent/WO2015160766A1/en not_active Ceased
- 2015-04-14 CA CA2945705A patent/CA2945705A1/en not_active Abandoned
- 2015-04-14 MX MX2016013340A patent/MX2016013340A/es unknown
- 2015-04-14 KR KR1020167031237A patent/KR20170005415A/ko not_active Ceased
- 2015-04-14 EA EA201692061A patent/EA201692061A1/ru unknown
-
2016
- 2016-10-09 IL IL248255A patent/IL248255A0/en unknown
- 2016-10-13 ZA ZA2016/07068A patent/ZA201607068B/en unknown
-
2019
- 2019-11-22 AU AU2019268190A patent/AU2019268190A1/en not_active Abandoned
-
2020
- 2020-03-04 JP JP2020036646A patent/JP2020105200A/ja active Pending
- 2020-05-06 US US16/868,365 patent/US20200360398A1/en not_active Abandoned
-
2022
- 2022-12-13 US US18/080,079 patent/US20230115839A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kadriu et al. | Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments | |
| US20240041900A1 (en) | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | |
| JP7012054B2 (ja) | 自閉症を治療するための医薬組成物 | |
| EP2272515A1 (en) | Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof | |
| KR20110010734A (ko) | 신생혈관형성증 조절을 통한 알츠하이머 질환 및 관련 장애의 치료를 위한 신규 치료학적 접근법 | |
| KR20110071050A (ko) | 알츠하이머 질환 및 관련 장애의 치료를 위한 조니사미드 및 아캄프로세이트의 조합 조성물 | |
| KR20110011628A (ko) | 세포 스트레스 반응 조절을 통한 알츠하이머 질환 및 관련 장애의 치료를 위한 신규 치료학적 접근법 | |
| JP2019524856A5 (enExample) | ||
| JP2016193932A5 (enExample) | ||
| JP2017535612A5 (enExample) | ||
| Stoopler et al. | Topical and systemic therapies for oral and perioral herpes simplex virus infections | |
| HRP20171739T1 (hr) | Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina | |
| JP5087280B2 (ja) | 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用 | |
| JP2017526693A5 (enExample) | ||
| RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
| CN113164488A (zh) | 慢性咳嗽治疗用药物 | |
| CA2816595A1 (en) | Combination therapy for the treatment of depression and other non-infectious diseases | |
| US20130017278A1 (en) | Composition and method for improving brain function | |
| JP2017511386A5 (enExample) | ||
| JP2020533296A5 (enExample) | ||
| JPWO2008090736A1 (ja) | アルツハイマー型認知症の予防及び治療のための医薬 | |
| JP4373087B2 (ja) | 痴呆治療剤 | |
| JP2018039810A5 (enExample) | ||
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| JP2019507786A5 (enExample) |